News Articles for Artrya

Listed medtech Artrya is seeking $80 million from investors to accelerate its commercial entry into the US market after gaining a key regulatory approval for its AI-powered healthcare tool.

Artrya has cleared a regulatory hurdle in the US, allowing it to charge fees for its AI-powered heart disease assessments.

Perth medtech Orthocell has appointed a former Pilbara Minerals figure and ex-Olympian to its executive team.

West Perth-based medtech Artrya has looked to co-founder John Konstantopoulos as it moves towards its US market launch.

West Perth medtech Artrya has signed a three-year deal to advance the screening and diagnosis of heart disease in Australia.

Our board moves wrap includes Mathew Regan, John Barrington, Philip Bainbridge, Kevin Tomlinson, Ray Shorrocks, Shaun Hardcastle, Tim Hannon, Brendan Power, John Baillie, John Dimitropoulos, Ross McKinnon, Ronnie Beevor, Michael O'Keeffe, Emily Spano, Peter Cook, Warren Hallam, Jonathan Shellabear, Rod Corps, and Teck Lim.

Medical technology company Artrya Limited has appointed experienced executive Mathew Regan as the company's new leader after its co-founder John Barrington resigned.

Our board moves wrap includes Kate Hill, John Konstantopoulos, Jocelyn Bennett, Frank Knezovic, William Witham, Matthew Kay, Hayden Bartrop, Jessamyn Lyons, David Groombridge, Jacqueline Murray, Xavier Braud, Trevor Bradley.

Mark Pownall and Mark Beyer discuss Mark McGowan's cabinet reshuffle, Clough, gas shortages, Genesis Minerals and St Barbara, CBH Group, the year in markets, HealthEngine, Artrya and the SKA.

Limitless: Having taken its AI technology to an IPO, Artrya is working to overcome regulatory hurdles.

Artrya's coronary diagnostic product has been given regulatory approval for use in the UK after being knocked back by the US Food and Drug Administration five months ago.

Our board moves wrap includes Steve Formica, Julian Jarman, Colin Locke, Mark Major, Kevin Hart, Nathan Bartrop, and Shaun Scott.

Our board moves wrap includes Jacque Sokolov, Adam Buckler, Bruce Nicholson, Aaron Bertolatti, Justin Osborne, Ian Murray, David Gurvey, Chris Bath, Peter Hatfull, and Elizabeth Henson.

A Perth-based artificial intelligence healthcare company has appointed a US health technology expert to its board.

Artrya shares continued to drop this morning after the US Food and Drug Administration knocked back its AI-based coronary diagnostic product for commercial use.

WA's health budget has tripled during the past 15 years, but there are concerns about patient outcomes amid workforce, bureaucracy and governance pressures.

Local medtech Artrya has listed on the stock exchange, having earlier raised $40 million through an IPO to help commercialise its cardiac imaging software.

Crawley-based Artrya has been shortlisted as a preferred supplier of AI software by the UK Health Service for its heart disease detection program.

A local medtech focused on the early detection of heart disease has sought $40 million through an IPO, which will in part be used to fund the development and commercialisation of its software.

Several exciting AI innovations are emerging from WA, and the world is watching.

PREDICTING if someone is at imminent risk of a heart attack has been for a long time the Holy Grail for heart researchers.